← Human Trials & Peer-Reviewed Studies
Growth hormone treatment improves body composition in adults with Prader-Willi syndrome.
Plain-language guide to PMID 12699450 (2003): open-label randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 12699450
- Journal
- Clinical endocrinology
- Year
- 2003
- Study type
- Randomized Controlled Trial
- Authors
- Höybye C et al. (4 authors)
- DOI
- 10.1046/j.1365-2265.2003.01769.x
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Low growth hormone (GH) secretion and hypogonadism are common in patients with Prader-Willi syndrome (PWS).
In this study the researchers present the effects of GH treatment on body composition and metabolism in adults with PWS.
Who Took Part
The age groups tagged for this paper are teenagers and adults, both men and women.
Nineteen patients with clinical PWS were recruited, 13 had PWS genotype.
Thereafter patients received open label treatment so that all had 12 months of active GH treatment.
How the Study Was Run
The design is described as randomized, open-label and placebo-controlled.
The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the participants and staff both knew the treatment.
A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.
Seventeen patients, nine men and eight women, 17-32 years of age, with a mean body mass index (BMI) of 35 +/- 3.2 kg/m2 completed the study.
What Was Measured
Topics PubMed links to this paper include Adipose Tissue, Body Composition, Body Mass Index, Genotype, Glucose Tolerance Test, Homeostasis and Human Growth Hormone.
What This Means in Plain Language
The paper is a randomized, open-label and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2003 (Clinical endocrinology), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.